HDL Deficiency: Unmasking the Genetic Culprits Behind Low "Good Cholesterol"
"Severe HDL deficiency isn't just a lifestyle issue; it often has deep genetic roots that significantly elevate cardiovascular disease risk. Are you at risk?"
For years, high-density lipoprotein (HDL), often dubbed “good cholesterol,” has been celebrated for its heart-protective qualities. It acts like a tiny vacuum cleaner, scooping up excess cholesterol from your arteries and ferrying it back to the liver for processing. But what happens when your HDL levels are stubbornly low? While lifestyle factors like diet and exercise play a significant role, sometimes, the real culprits are lurking in your genes.
A groundbreaking study published in the Journal of Lipid Research sheds light on the genetic and secondary causes of severe HDL deficiency. This research assessed over 258,000 subjects, pinpointing specific genetic mutations that contribute to alarmingly low HDL levels and a heightened risk of atherosclerotic cardiovascular disease (ASCVD).
This article dives deep into the findings, offering you a comprehensive guide to understanding the genetic underpinnings of HDL deficiency. We'll explore which genes are most frequently involved, how these mutations impact your heart health, and what steps you can take to mitigate your risk.
Genetic Testing Thresholds and Practice
Genetic testing can assess variants responsible for extreme HDL-C levels and help evaluate whether current testing thresholds are adequate. A 2023 practical approach describes genetic testing for severe deviations in HDL, LDL, triglycerides, combined hyperlipidaemia, and dysbetalipoproteinemia. Findings from the Tromsø Study report that HDL-related genetic testing is underused and that many individuals with pathogenic variants do not meet current extreme HDL-C criteria. The study proposes revised sex-specific thresholds to improve identification and diagnosis of HDL-related disorders.
From HDL Deficiency to Gene Discovery
Familial HDL deficiency is described as a rare condition characterized by low levels of high-density lipoprotein in the blood. HDL transports cholesterol and phospholipids from body tissues to the liver, where they can be redistributed. The NIH Genetic Testing Registry notes that hypoalphalipoproteinemia, or HDL deficiency, has been linked to early familial coronary heart disease and increased cardiovascular disease risk. Molecular work has also produced methods for scanning the ABCA1 gene for mutations in familial high-density lipoprotein deficiency.
Decoding the Genetic Landscape of HDL Deficiency: What Genes Are Involved?
The Journal of Lipid Research study meticulously sequenced 23 lipid-related genes in participants with severe HDL deficiency (defined as HDL-C levels below 20 mg/dL). The results revealed that a significant portion of these individuals carried mutations in key genes responsible for regulating HDL metabolism:
- ABCA1 (ATP-binding cassette transporter A1): This gene plays a vital role in cholesterol efflux, the process by which cells release cholesterol to be picked up by HDL. Mutations in ABCA1 can impair this process, leading to a buildup of cholesterol in the arteries and low HDL levels. Approximately 26.9% of the study participants with HDL deficiency had mutations in this gene.
- LCAT (Lecithin-cholesterol acyltransferase): LCAT is an enzyme that modifies cholesterol in HDL, helping it to mature and carry more cholesterol. Mutations in LCAT can lead to dysfunctional HDL particles, resulting in cholesterol buildup. 12.4% of the subjects showed mutation in this gene.
- APOA1 (Apolipoprotein A1): APOA1 is the main protein component of HDL, providing its structural framework and facilitating cholesterol binding. Mutations in APOA1 can affect the stability and function of HDL, contributing to its deficiency. 5.0% of the participants showed mutation in this gene.
- LPL (Lipoprotein Lipase): While primarily known for its role in breaking down triglycerides, LPL also indirectly influences HDL levels. Certain variants in LPL were found in 4.5% of participants and were associated with hypertriglyceridemia, which often accompanies low HDL.
HDL Particle Biology and Genetic Disorders
A 2025 review describes HDL as a population of particles with different sizes and compositions, including very-large alpha-1-HDL particles measuring about 11.0 nm and comprising about 22% of HDL particles. Familial apoA-I deficiency, LCAT deficiency, and ABCA1 deficiency, also called Tangier disease, can produce low HDL particle levels. Tangier disease was first described by Donald Fredrickson and colleagues in two children from Tangier Island in the Chesapeake Bay, who had enlarged orange tonsils containing cholesteryl esters, hepatosplenomegaly, mild corneal opacification, and marked HDL deficiency. A 2025 report from Israel further describes three genetically determined cases of HDL-C deficiency identified through genetic evaluation.
Take Control of Your Heart Health
If you have a family history of low HDL or premature heart disease, or you are looking for peace of mind, consult your doctor about genetic testing of the related genes to make sure your heart is in great condition. Knowing your genetic predisposition can empower you to make informed decisions about your lifestyle, diet, and potential medical interventions.
Where Genetic Testing Has Clinical Utility
The National Lipid Association scientific statement identifies genetic testing as increasingly relevant in clinical dyslipidemia care. It lists familial hypercholesterolemia, familial chylomicronemia syndrome, sitosterolemia, lysosomal acid lipase deficiency, and several other rare disorders as conditions in which testing may have clinical utility. The statement also anticipates greater demand for reliable genetic diagnostic methods at lower cost. These recommendations place genetic testing within a broader framework for distinguishing monogenic and polygenic lipid disorders.
Cases That Make Genetic Findings Actionable
A 2021 Frontiers case report examined two probands with coexisting growth hormone deficiency and familial hypercholesterolemia. The patients underwent evaluations that included blood and urine testing, thyroid and gonadal function tests, serum insulin-like growth factor-1 measurement, and growth hormone stimulation tests. A 2025 GB HealthWatch case study highlights how genetic testing and analysis can help investigate difficult cases involving statin intolerance, high HDL, and severe hypercholesterolemia. Together, these reports illustrate how genetic evaluation may be used to investigate complex or unexpected lipid-related presentations.